35 Gatehouse Drive
Building D Floor 3
Waltham, MA 02451
United States
781 419 1400
https://www.syndax.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 184
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Mr. Michael A. Metzger M.B.A. | CEO & Director | 1.02M | 116.7k | 1971 |
Dr. Neil Gallagher M.D., Ph.D. | President, Head of Research & Development | 663.73k | N/A | 1964 |
Mr. Keith Alan Goldan CPA | CFO, Treasurer & Chief Accounting Officer | 621.53k | N/A | 1971 |
Mr. Luke J. Albrecht | Senior VP, General Counsel & Secretary | 581.65k | 356.87k | 1979 |
Dr. Catherine Madigan M.D. | Chief Medical Officer | 604.21k | N/A | 1972 |
Dr. Peter Ordentlich B.Sc., Ph.D. | Co-Founder & Chief Scientific Officer | N/A | N/A | 1969 |
Dr. Richard A. Heyman Ph.D. | Co-Founder | N/A | N/A | 1957 |
Dr. Ronald M. Evans Ph.D. | Co-Founder, Advisor and Chair of Scientific Advisory Board | N/A | N/A | 1949 |
Dr. Michael Downes Ph.D. | Co-Founder | N/A | N/A | N/A |
Sharon Klahre | Vice President of Investor Relations & Communications | N/A | N/A | N/A |
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Syndax Pharmaceuticals, Inc.’s ISS governance QualityScore as of 1 May 2024 is 7. The pillar scores are Audit: 6; Board: 6; Shareholder rights: 8; Compensation: 7.